GANX GANX
Company Profile ↓Company Overview
GANX (GANX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 24.1% CAGR over the past five years.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -58.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 24.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 24.09% |
| 1 Year: | -58.40% |
Stock Price Performance
| 1 Year: | +22.45% |
| 6 Months: | -0.55% |
| 3 Months: | -3.74% |
| 1 Month: | -0.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.95 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 24.1% over 5 years.
CONS
- Trading 56.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 81.62K | 15.97K | 37.54K | 95.10K | - | 55.18K | - | - | - | - | - | - | - | - | - |
| Operating Income | -512.26K | -532.47K | -819.09K | -2.47M | -3.51M | -4.64M | -3.29M | -5.18M | -4.75M | -5.23M | -7.73M | -4.89M | -4.38M | -8.18M | -4.46M | -4.37M | -5.09M | -4.79M | -5.35M |
| Net Income | -584.27K | -543.36K | -794.37K | -2.45M | -3.56M | -4.66M | -3.27M | -5.09M | -4.56M | -5.14M | -7.69M | -4.72M | -4.01M | -8.14M | -4.49M | -4.53M | -5.81M | -5.28M | -5.61M |
| Diluted EPS | - | -0.27 | -0.25 | -0.50 | -0.30 | -0.39 | -0.28 | -0.43 | -0.38 | -0.43 | -0.62 | -0.37 | -0.22 | -0.42 | -0.17 | -0.16 | -0.19 | -0.15 | -0.13 |
| R&D Expense | 417.26K | 438.87K | 427.46K | 1.42M | 1.79M | 2.48M | 1.56M | 2.58M | 1.96M | 2.79M | 3.99M | 2.37M | 2.51M | 4.44M | 2.62M | 2.26M | 2.76M | 2.85M | 2.76M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 28.88K | 133.93K | 132.64K | 55.18K | - | - |
| Operating Income | -3.48M | -13.83M | -17.78M | -22.25M | -20.35M | -18.71M |
| Net Income | -3.58M | -13.89M | -17.59M | -22.27M | -20.41M | -20.16M |
| Diluted EPS | -1.33 | -1.37 | -1.48 | -1.71 | -0.89 | -0.61 |
| R&D Expense | 2.26M | 7.16M | 8.38M | 11.52M | 10.79M | 10.21M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.60M | 38.99M | 24.10M | 18.61M | 12.12M | 22.82M |
| Total Equity | -449.86K | 6.20M | 34.82M | 18.88M | 12.58M | 7.34M | 18.56M |
| Cash & Equivalents | - | 7.49M | 36.88M | 7.31M | 11.79M | 10.39M | 20.84M |
| Long Term Debt | - | 715.66K | 590.47K | 495.26K | 449.05K | 328.33K | 300.08K |
| Total Liabilities | - | 3.40M | 4.17M | 5.22M | 6.03M | 4.78M | 4.25M |
| Current Liabilities | - | 2.11M | 2.55M | 4.13M | 4.95M | 3.91M | 3.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.24M | -12.37M | -14.69M | -18.87M | -18.87M | -18.47M |
| Investing Cash Flow | -20.83K | -94.21K | -14.77M | 10.22M | 4.98M | - |
| Financing Cash Flow | 10.49M | 41.77M | -78.77K | 12.64M | 13.01M | 28.45M |
| Capital Expenditure | -20.83K | -94.21K | - | - | - | - |
| Free Cash Flow | -3.26M | -12.46M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -12,047.5% | -10,323.6% | -13,402.5% | -40,328.3% | - | - |
| Net Margin % | -12,387.7% | -10,371.7% | -13,262.0% | -40,354.3% | - | - |
| ROE % | -57.7% | -39.9% | -93.2% | -177.0% | -278.1% | -108.6% |
| ROCE % | -46.5% | -38.0% | -89.0% | -162.9% | -247.8% | -96.1% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GANX
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNMFFpOWNoOEhDSXBMaWpoLXBmQkVkS1pZZ0JRSF9Ibk8xRGNpeVlzc2h3MkRiVnhwa3pPOXg3d2UwNE9FbVpGblZRVnAxMkttN3FmWVU4VnpROXlWSEpKeWw5aVVqQ3lyNmtpaUtwZDNROGdwWDY3WFNDOWFmQVQ5emF2VUZ4aFlaYngzVE…
Why Is GANX Stock Rallying 22% After Hours? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPbzVDdTltMGJCVVAxTDFIa2RDVUFmVnRjYlhqYUdsZ21lZ2g2MFVpbWVtUVFzUVlSQTllcVBwdkY4R1UtODY4ZExza0tMbE02Uk04MFR3N2RPdWN6T2FTSG5rMjgxUXptU0JEUDQ4bnpBUE1Cc21kOXMtOUdwN1Z0R0xIdzVTMHBxWm5IM0…
FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson’s trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQZFVEU1BYbmR2cWZEZExaaTVzc1FTdnl2VndNVnB0UVNYczZHOVdTVF92bDNFT1pvN2RBZDl0LVh2OFhSckJoaDJDWjdvVm9yZTBZVmQ3NUxNNElrM050MmxZTUMyeTJrQVUxNk5jenRVbW0xcGtUcVFzMHRZTm9RVEd1Q1B0Q1QtMU5tSm…
GANX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBSQjNsUmxuQ1NEZ0NQOHV0b1EyVXJJazdDOGJGdUtnUzUtMnRJS1paZkFOX2g1NzdVaDBmOHgyTEhCVEZpYWtHZ01SWUV4WktkZ3E4Tkoxb183cFN2Q0RNc21VRVV1Ums2cTZBRUNsaVAwUDFETHJHemJR?oc=5" target="_blank">GAN…
Gain Therapeutics, Inc. Common Stock (GANX) Stock Price Today: $1.73 - Gotrade
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTFBtRl93Ri1WZzVlSGhCWHhnSHAxV1kzWlg4UU9tR1BqSjBjSEdnT3huUDJDaDAwX3d3QmpzdWVHNzliWjNKdGNsVnMwZXF5dy1DdGxnVUtRMA?oc=5" target="_blank">Gain Therapeutics, Inc. Common Stock (GANX) Stock…
GANX | Gain Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBWS3RXREJELUd6YXJaYXNPbzVJQWR0UWhJSXJXUTNUUUxkT1Z1cUMyYTZnWVZ0YWtWUTgzbGw0NEtjMnpfTlZJNDJNa1k5NFJFQXNKbGdrZW8zb0hB?oc=5" target="_blank">GANX | Gain Therapeutics, Inc. Common Insid…
GANX — Frequently Asked Questions
What is the current share price of GANX?
As of 2026-08-05 17:25 PDT, GANX trades at $1.80 on NASDAQ/NYSE. Its 52-week range is $1.46 to $4.18.
What is the P/E ratio of GANX?
GANX trades at a trailing price-to-earnings (P/E) ratio of -2.95.
What is the return on equity (ROE) of GANX?
GANX has a return on equity (ROE) of -108.60%. Its return on capital employed (ROCE) is -96.12%.
Is GANX a good stock to buy?
This page provides a data-driven analysis of GANX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.